Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
About
  2. products
  3. non allergenic metallic urethral stent

Memokath -Model 044 -Non-Allergenic Metallic Urethral Stent

SHARE

Memokath™ 044 Urethra is a non-allergenic metallic stent used to effectively treat bulbar urethral stricture without the side-effects of major surgery, or discomfort of catheters. Memokath™ 044 Urethra is a non-allergenic metallic stent used to effectively treat bulbar urethral stricture. The stent is typically inserted in 30-45 minutes under local anesthesia through the urethra with a cystoscope and positioned across the stricture to allow urine to flow through the urethra. Memokath™ 044 Urethra preserves normal bladder control and provides urinary flow without the side-effects of major surgery and discomfort of catheters. It can remain inside the body for several years before needing replacement.


Most popular related searches
urethral stricture
urinary infection
urethral
urethral stent
disease patient
stent removal
bladder control
urinary flow
urinary tract
patient safety

Memokath™ 044 Urethra is used for bulbar urethral strictures. It treats strictures without the debilitating side-effects of surgery, and discomfort of catheters making it a preferred choice for patients who wish to avoid these. The effectiveness and long-term patency of Memokath™ 044 Urethra also makes it viable solution for patients who receive incisions or dilatations regularly, as well as for patients of high age, frailty, or on anticoagulant medicine.

  • Indications

    Bulbar urethral strictures

  • Etiology

    Trauma
    Instrumentations
    Sexually transmitted diseases

  • Patient examples

    Patients receiving repeat incisions or dilations
    Patients on catheters
    Patients unwilling to undergo surgery
    Patients for whom surgery has failed
    Patients of high age or frailty
    Patients on anticoagulant medicine

Memokath™ 044 Urethra is chosen as treatment method against bulbar urethral strictures due to its advantages over competing treatments. Memokath™ 044 Urethra offers a high degree of patient safety and quality of life by avoiding the debilitating side-effects of e.g. impotence, incontinence and urinary tract infections observed with competing treatments. Through its extended insitu time among other factors and Memokath™ 044 Urethra is moreover a sound economic choice of treatment with the potential to save substantial costs compared to surgery and catherization and has demonstrated a high rate of long-term stricture resolution after stent removal.

Safety

00% reversible
Causes minimal risk of infection
Minimal tissue in-growth risk
No need for general anaesthesia
Replaces need for surgery

Quality of Life

High rate of stricture resolution
Retains voluntary urination control
Replaces need for catheters
Low risk of infection

Cost effectiveness

Fewer switches than with catheters
Out-patient procedure of app. 45 min.
Immediate return to daily activities
Easy to exchange when needed
Immediate symptom relief

Memokath™ 044 Urethra generally causes few and only minor side-effects. Blood may occur in the patients’ urine for a period after the insertion, which is normal. The risk of complications is also minor and pertains to stent migration or encrustation. If the stent migrates, it can often be repositioned. If not, it can simply be removed or exchanged with a new stent. If the stent encrusts it will typically have to be exchanged. Vigilance by both patients and doctors towards recouping symptoms is always recommended to avoid complete encrustation. Due to the curvature of the urethra, Memokath™ 044 Urethra has in some cases been known to cause slight tissue ingrowth, but rarely to an extent affecting ease of exchange or removal.